Eran Rotem - 03 Sep 2026 Form 4 Insider Report for CollPlant Biotechnologies Ltd (CLGN)

Reporting relationship: Deputy CEO and CFO
Issuer ticker: CLGN
Reported as of: 03 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Sep 2026, 16:05:15 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Eran Rotem

Key filing fact

Eran Rotem filed Form 4 for CollPlant Biotechnologies Ltd (CLGN) on 08 Sep 2026.

Key facts

This page summarizes Eran Rotem's Form 4 filing for CollPlant Biotechnologies Ltd (CLGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Sep 2026, 16:05.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001423145 Primary reporting owner

Rotem Eran

Relationship: Deputy CEO and CFO
Address: C/O COLLPLANT BIOTECHNOLOGIES LTD., 4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK, REHOVOT, ISRAEL
Signature: /s/ Eran Rotem
Signature date: 08 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLGN transaction

Ordinary Shares

Award

Transaction value
Shares: +510,372
Change %: +8506%
Price: $0.000000^*
Shares after: 516,372
Date: 03 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent right to receive one ordinary share, no par value per share, of the Issuer ("Ordinary Shares"). The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%) of the RSUs vest on September 3, 2027, and the remaining seventy percent (70%) vest in equal installments every three months thereafter over the following four years, such that the RSUs will be fully vested on September 3, 2031, subject to the Reporting Person's continued service to the Company through each vesting date.

Footnote F2

Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Footnote F3

The total reported in Column 5 includes (i) 510,372 newly-awarded RSUs, (ii) 3,375 Ordinary Shares, and (iii) 2,625 previously-awarded RSUs.